Cargando…
PML isoforms in response to arsenic: high-resolution analysis of PML body structure and degradation
Arsenic is a clinically effective treatment for acute promyelocytic leukaemia (APL) in which the promyelocytic leukaemia (PML) protein is fused to retinoic receptor alpha (RARα). PML-RARα is degraded by the proteasome by a SUMO-dependent, ubiquitin-mediated pathway in response to arsenic treatment,...
Autores principales: | Hands, Katherine J., Cuchet-Lourenco, Delphine, Everett, Roger D., Hay, Ronald T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Company of Biologists
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3889398/ https://www.ncbi.nlm.nih.gov/pubmed/24190887 http://dx.doi.org/10.1242/jcs.132290 |
Ejemplares similares
-
The p97/VCP segregase is essential for arsenic-induced degradation of PML and PML-RARA
por: Jaffray, Ellis G., et al.
Publicado: (2023) -
Requirement of PML SUMO Interacting Motif for RNF4- or Arsenic Trioxide-Induced Degradation of Nuclear PML Isoforms
por: Maroui, Mohamed Ali, et al.
Publicado: (2012) -
Arsenic-Induced SUMO-Dependent Recruitment of RNF4 into PML Nuclear Bodies
por: Geoffroy, Marie-Claude, et al.
Publicado: (2010) -
PML Degradation: Multiple Ways to Eliminate PML
por: Rabellino, Andrea, et al.
Publicado: (2013) -
Acute promyelocytic leukemia, arsenic, and PML bodies
por: de Thé, Hugues, et al.
Publicado: (2012)